Literature DB >> 10079253

Urinary bladder transitional cell carcinogenesis is associated with down-regulation of NF1 tumor suppressor gene in vivo and in vitro.

V Aaltonen1, P J Boström, K O Söderström, O Hirvonen, J Tuukkanen, M Nurmi, M Laato, J Peltonen.   

Abstract

The NF1 gene product (neurofibromin) is known to act as a tumor suppressor protein by inactivating ras. The best documented factors involved in urinary bladder transitional cell carcinoma (TCC) are ras proto-oncogene activation and p53 suppressor gene mutations. This is the first study reporting alterations in NF1 gene expression in TCC. We examined NF1 gene expression in a total of 29 surgical urinary bladder TCC specimens representing grades 1 to 3 and in three cell lines, RT4, 5637, and T24 (representing grades 1 to 3, respectively). Decreased NF1 gene expression was observed in 23 of 29 (83%) TCC specimens as estimated by immunohistochemistry, the decrease being more pronounced in high-grade tumors. NF1 mRNA levels were markedly lower in TCC tissue compared with adjacent non-neoplastic urothelium, as studied by in situ hybridization for grade 3 TCC. Immunohistochemistry and Western blotting demonstrated that TCC cell lines expressed NF1 protein at different levels, expression being almost undetectable in T24 (grade 3) cells. Northern blotting for cell lines demonstrated reduced NF1 mRNA levels in grade 3 TCC cells. Reverse transcription polymerase chain reaction for cell lines and selected grade 2 and grade 3 tissue samples demonstrated NF1 type II mRNA isoform predominance in all samples studied. Our results show that both NF1 mRNA and protein levels are decreased in high-grade TCC, suggesting that alterations of NF1 gene expression may be involved in bladder TCC carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10079253      PMCID: PMC1866425          DOI: 10.1016/S0002-9440(10)65322-9

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  52 in total

Review 1.  Molecular and immunopathology studies of oncogenes and tumor-suppressor genes in bladder cancer.

Authors:  C Cordon-Cardo; J Sheinfeld
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

Review 2.  Upregulation of tumor suppressor protein neurofibromin in normal human wound healing and in vitro evidence for platelet derived growth factor (PDGF) and transforming growth factor-beta1 (TGF-beta1) elicited increase in neurofibromin mRNA steady-state levels in dermal fibroblasts.

Authors:  H Ylä-Outinen; V Aaltonen; A S Björkstrand; O Hirvonen; J Lakkakorpi; M Vähä-Kreula; M Laato; J Peltonen
Journal:  J Invest Dermatol       Date:  1998-03       Impact factor: 8.551

3.  Increased neurofibromatosis 1 gene expression in astrocytic tumors: positive regulation by p21-ras.

Authors:  D H Gutmann; M J Giordano; D K Mahadeo; N Lau; D Silbergeld; A Guha
Journal:  Oncogene       Date:  1996-05-16       Impact factor: 9.867

4.  Lesional psoriatic epidermis displays reduced neurofibromin immunoreactivity.

Authors:  J Peltonen; S L Karvonen; H Ylä-Outinen; O Hirvonen; J Karvonen
Journal:  J Invest Dermatol       Date:  1995-11       Impact factor: 8.551

5.  Loss of neurofibromatosis type I (NF1) gene expression in pheochromocytomas from patients without NF1.

Authors:  D H Gutmann; R T Geist; K Rose; G Wallin; J F Moley
Journal:  Genes Chromosomes Cancer       Date:  1995-06       Impact factor: 5.006

Review 6.  Ras target proteins in eukaryotic cells.

Authors:  M S Marshall
Journal:  FASEB J       Date:  1995-10       Impact factor: 5.191

Review 7.  Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling.

Authors:  D T Denhardt
Journal:  Biochem J       Date:  1996-09-15       Impact factor: 3.857

8.  On unequal allelic expression of the neurofibromin gene in neurofibromatosis type 1.

Authors:  S Hoffmeyer; G Assum; J Griesser; D Kaufmann; P Nürnberg; W Krone
Journal:  Hum Mol Genet       Date:  1995-08       Impact factor: 6.150

9.  Infrequent involvement of mutations on neurofibromatosis type 1, H-ras, K-ras and N-ras in urothelial tumors.

Authors:  T Uchida; C Wada; H Ishida; S Egawa; T Ao; E Yokoyama; K Koshiba
Journal:  Urol Int       Date:  1995       Impact factor: 2.089

Review 10.  Neurofibromatosis type 1: pathology, clinical features and molecular genetics.

Authors:  A von Deimling; W Krone; A G Menon
Journal:  Brain Pathol       Date:  1995-04       Impact factor: 6.508

View more
  8 in total

Review 1.  The NF1 somatic mutational landscape in sporadic human cancers.

Authors:  Charlotte Philpott; Hannah Tovell; Ian M Frayling; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2017-06-21       Impact factor: 4.639

2.  NF1 gene loss of heterozygosity and expression analysis in sporadic colon cancer.

Authors:  T Cacev; S Radosević; R Spaventi; K Pavelić; S Kapitanović
Journal:  Gut       Date:  2005-04-19       Impact factor: 23.059

3.  The neurofibromatosis type 1 (Nf1) tumor suppressor is a modifier of carcinogen-induced pigmentation and papilloma formation in C57BL/6 mice.

Authors:  R P Atit; K Mitchell; L Nguyen; D Warshawsky; N Ratner
Journal:  J Invest Dermatol       Date:  2000-06       Impact factor: 8.551

4.  Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations.

Authors:  Navneet Sangha; Rong Wu; Rork Kuick; Scott Powers; David Mu; Diane Fiander; Kit Yuen; Hidetaka Katabuchi; Hironori Tashiro; Eric R Fearon; Kathleen R Cho
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

Review 5.  Role of p38 MAP Kinase Signal Transduction in Solid Tumors.

Authors:  Hari K Koul; Mantu Pal; Sweaty Koul
Journal:  Genes Cancer       Date:  2013-09

6.  Implication of vascular endothelial growth factor A and C in revealing diagnostic lymphangiogenic markers in node-positive bladder cancer.

Authors:  Cédric Poyet; Linto Thomas; Tobias M Benoit; David Aquino Delmo; Laura Luberto; Irina Banzola; Michèle S Günthart; Giovanni Sais; Daniel Eberli; Tullio Sulser; Maurizio Provenzano
Journal:  Oncotarget       Date:  2017-03-28

7.  Targeted therapies in the management of metastatic bladder cancer.

Authors:  Matteo Fassan; Edouard J Trabulsi; Leonard G Gomella; Raffaele Baffa
Journal:  Biologics       Date:  2007-12

8.  Functional expression of NF1 tumor suppressor protein: association with keratin intermediate filaments during the early development of human epidermis.

Authors:  Maria Malminen; Sirkku Peltonen; Jussi Koivunen; Juha Peltonen
Journal:  BMC Dermatol       Date:  2002-08-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.